Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid steps onto world stage for hair research in Japan

The three-day conference program begins Wednesday 1 November, 2017.
Audience listens to the speech of the lecturer in the conference hall
The forum is attended by over 700 leading international scientists and clinicians

Cellmid (ASX:CDY) will be presenting the recently published FGF5 inhibitor clinical data at the World Congress for Hair Research in Kyoto, Japan.

Dr Dominic Burg will be presenting the results of the recently published clinical study describing the efficacy of the FGF5 inhibiting évolis® tonic formulation.

The talk will be given on the first day and in front of the entire congress, making it one of the most significant presentations during the three days of proceedings.

Key findings of the recently published clinical study demonstrated that topical use of évolis® was effective against hair loss in men and women.

Over 16 weeks of treatment évolis®:

- Reduced hair loss by 82%;
- Increased the rate of actively growing hair follicles by 44%; and
- Improved hair density.

World Congress for Hair Research

The World Congress for Hair Research is the preeminent scientific meeting for hair science, organised by several international organisations including The Society for Hair Science Research and the North American Hair Research Society.

The congress is attended by more than 700 hair biologists, dermatologists, cosmetic scientists and hair transplantation surgeons from over 50 countries.

The presentation of results on the use of Advangen’s FGF5 inhibiting topical formulation to such an internationally recognised expert audience will provide an excellent avenue for exposure of the company’s technology, compelling clinical data and products.

A second abstract on the Cellmid’s FGF5 technology will be presented in the form of a scientific poster, a common occurrence at the conference.


Cellmid has two business segments - consumer health and its midkine (MK) portfolio.

The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.

During the recent September quarter, the consumer health segment achieves sales of $1.03 million, up 4% on the prior corresponding quarter.

The majority of sales are generated in Japan and Cellmid most recently launched its lead revenue driving évolis® hair loss products into the U.S. market.

Cellmid finished the September quarter with circa $2.9 million in cash, which didn’t include the $0.95 million tax credit received in early October.

The company recently opened its first Advangen Hair Biology concept store in Tokyo, Japan.

READ NOW: Cellmid lifts revenue options after taking clinically validated hair products to Tokyo

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use